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tective effect of stiripentol’
Dear Sir,
Goorhuis et al. add some very important information
about the problem of medication-induced hepato-
toxicity in children with Dravet syndrome. The girl
they describe was treated with valproic acid, stir-
ipentol and acetaminophen. Stiripentol is thought
to prevent liver damage in acetaminophen intoxica-
tion. Stiripentol inhibits the synthesis of N-acetyl-p-
benzoquinone-imine, a highly reactive acetamino-
phen-metabolite.1 In rats, stiripentol is able to
prevent hepatic necrosis after acetaminophen over-
dose1 and in 24 children treated with the combina-
tion of stiripentol, VPA, and TPM, no liver problems
have been reported.2
The four children we have described and the girl
described by Goorhuis et al. have in common that
they all used valproic acid and acetaminophen,
which strongly favours the hypothesis that this com-
bination is causing hepatotoxicity.
Recently, at the 7th EPNS congress in Kusadasi,
Turkey, a poster was presented of a 4-year-old boy
with Dravet syndrome suffering from severe hepatic
damage and hyperammonemia after treatment with
valproic acid and phenobarbitone.3 Also in this case,
liver problems developed after he had been givenDOIs of original articles: 10.1016/j.seizure.2007.07.003., 10.1016
1059-1311/$ — see front matter # 2008 British Epilepsy Association
doi:10.1016/j.seizure.2008.03.001acetaminophen (personal communication Dr Abu-
Rashed).
We do agree with Goorhuis et al. that the use of
acetaminophen in children with Dravet syndrome
who are on valproic acid therapy may induce acute
hepatic injury.References
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